FIELD: biotechnology.
SUBSTANCE: antibodies that bind to HLA-A2/WT1 and bispecific antigen-binding molecules that bind to HLA-A2/WT1 and CD3 are provided. The invention further relates to polynucleotides encoding such antibodies or bispecific antigen binding molecules, as well as expression vectors and host cells comprising such polynucleotides. The invention also relates to methods for producing antibodies and bispecific antigen-binding molecules and methods of using them for the treatment of cancer.
EFFECT: invention provides enhanced inhibition of tumour growth.
44 cl, 43 dwg, 8 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| DIVALENT BISPECIFIC CHIMERIC ANTIBODY COMPRISING HETERODIMER BASED ON MHC OR MHC-LIKE PROTEINS | 2021 |
|
RU2820683C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BINDING MOLECULES INDUCING CELLULAR ACTIVATION | 2019 |
|
RU2770620C1 |
